{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=17", "query": { "condition": "Differentiation", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 406, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Differentiation&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T16:19:01.122Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00634244", "title": "Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 92, "start_date": "2008-10", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-07-07", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634244" }, { "nct_id": "NCT02592356", "title": "Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Malignant Adrenal Gland Pheochromocytoma", "Malignant Paraganglioma", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dual X-ray Absorptiometry", "type": "PROCEDURE" }, { "name": "Physical Examination", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2015-11-16", "completion_date": "2024-03-01", "has_results": false, "last_update_posted_date": "2024-03-05", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02592356" }, { "nct_id": "NCT07529080", "title": "Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Differentiated Thyroid Gland Carcinoma", "Malignant Testicular Neoplasm", "Melanoma", "Thyroid Gland Follicular Carcinoma", "Thyroid Gland Papillary Carcinoma" ], "interventions": [ { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Interview", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "20 Years to 39 Years" }, "enrollment_count": 142, "start_date": "2026-12", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07529080" }, { "nct_id": "NCT03896958", "title": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, All Types", "Cancer of Liver", "Cancer of Stomach", "Cancer of Head and Neck", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Colon", "Cancer Skin", "Cancer of Cervix", "Cancer, Metastatic", "Cancer of Larynx", "Cancer of Neck", "Cancer of Lung", "Cancer of Brain and Nervous System", "Cancer of Vulva, Disseminated", "Cancer of Pancreas", "Sarcoma", "GIST", "Small-cell Lung Cancer", "Adenocarcinoma Lung", "Cancer of Prostate", "Cancer, Advanced", "Adrenal Cancer", "Testicular Cancer", "Uterine Cancer", "Bronchoalveolar Cell Lung Cancer", "Cancer Unknown Primary", "Glioblastoma Multiforme", "Oligodendroglioma", "Breast Cancer", "Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Squamous Cell Carcinoma", "Transitional Cell Carcinoma", "Cancer, Other", "Cancer, Anal", "Melanoma", "Cancer, Bile Duct", "Cancer, Bladder", "Cancer Cords Vocal", "Cancers Cell Neuroendocrine", "Cancer Differentiated Poorly", "Cancer, Anaplastic Thyroid" ], "interventions": [], "intervention_types": [], "sponsor": "SpeciCare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "99 Years", "sex": "ALL", "summary": "1 Month to 99 Years" }, "enrollment_count": 1000, "start_date": "2019-03-21", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2020-12-04", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 1, "location_summary": "Gainesville, Georgia", "locations": [ { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896958" }, { "nct_id": "NCT01132547", "title": "Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cyproheptadine hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 22, "start_date": "2010-06", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-07-02", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 14, "location_summary": "Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132547" }, { "nct_id": "NCT01127009", "title": "Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2010-07", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2015-08-13", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01127009" }, { "nct_id": "NCT06959641", "title": "XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Differentiated Thyroid Gland Carcinoma", "Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma", "Locally Advanced Thyroid Gland Follicular Carcinoma", "Locally Advanced Thyroid Gland Oncocytic Carcinoma", "Locally Advanced Thyroid Gland Papillary Carcinoma", "Metastatic Differentiated Thyroid Gland Carcinoma", "Metastatic Poorly Differentiated Thyroid Gland Carcinoma", "Metastatic Thyroid Gland Follicular Carcinoma", "Metastatic Thyroid Gland Oncocytic Carcinoma", "Metastatic Thyroid Gland Papillary Carcinoma", "Refractory Differentiated Thyroid Gland Carcinoma", "Refractory Poorly Differentiated Thyroid Gland Carcinoma", "Refractory Thyroid Gland Follicular Carcinoma", "Refractory Thyroid Gland Oncocytic Carcinoma", "Refractory Thyroid Gland Papillary Carcinoma", "Stage III Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage III Thyroid Gland Follicular Carcinoma AJCC v8", "Stage III Thyroid Gland Papillary Carcinoma AJCC v8", "Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8", "Stage IV Thyroid Gland Follicular Carcinoma AJCC v8", "Stage IV Thyroid Gland Papillary Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Zanzalintinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Jochen Lorch", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2025-06-06", "completion_date": "2030-09-11", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 2, "location_summary": "Torrance, California • Chicago, Illinois", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06959641" }, { "nct_id": "NCT00096122", "title": "Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Childhood Myelodysplastic Syndromes", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndromes", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "tipifarnib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 95, "start_date": "2004-09", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2014-05-26", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096122" }, { "nct_id": "NCT05247905", "title": "Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Neuroendocrine Tumor", "Unresectable Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2023-02-16", "completion_date": "2033-04-01", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 171, "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Dublin", "state": "California" }, { "city": "Emeryville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05247905" }, { "nct_id": "NCT02833844", "title": "Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection" ], "interventions": [ { "name": "Evolocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 467, "start_date": "2017-05-22", "completion_date": "2020-01-27", "has_results": true, "last_update_posted_date": "2022-07-22", "last_synced_at": "2026-10-27T16:19:01.122Z", "location_count": 20, "location_summary": "Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02833844" } ] }